These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 26431982)

  • 21. A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia.
    Doherty JF; Pinder M; Tornieporth N; Carton C; Vigneron L; Milligan P; Ballou WR; Holland CA; Kester KE; Voss G; Momin P; Greenwood BM; McAdam KP; Cohen J
    Am J Trop Med Hyg; 1999 Dec; 61(6):865-8. PubMed ID: 10674660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of the RTS,S/AS malaria candidate vaccine.
    Vekemans J; Leach A; Cohen J
    Vaccine; 2009 Dec; 27 Suppl 6():G67-71. PubMed ID: 20006143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S/AS01 in endemic Africa.
    Galactionova K; Tediosi F; Camponovo F; Smith TA; Gething PW; Penny MA
    Vaccine; 2017 Jan; 35(1):53-60. PubMed ID: 27890400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Immunogenicity of Seven Dosing Regimens of the Candidate RTS,S/AS01E Malaria Vaccine Integrated Within an Expanded Program on Immunization Regimen: A Phase II, Single-Center, Open, Controlled Trial in Infants in Malawi.
    Witte D; Cunliffe NA; Turner AM; Ngulube E; Ofori-Anyinam O; Vekemans J; Chimpeni P; Lievens M; Wilson TP; Njiram'madzi J; Mendoza YG; Leach A
    Pediatr Infect Dis J; 2018 May; 37(5):483-491. PubMed ID: 29432383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A.
    Walsh DS; Gettayacamin M; Leitner WW; Lyon JA; Stewart VA; Marit G; Pichyangkul S; Gosi P; Tongtawe P; Kester KE; Holland CA; Kolodny N; Cohen J; Voss G; Ballou WR; Heppner DG
    Vaccine; 2006 May; 24(19):4167-78. PubMed ID: 16574282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone.
    Stewart VA; McGrath SM; Dubois PM; Pau MG; Mettens P; Shott J; Cobb M; Burge JR; Larson D; Ware LA; Demoitie MA; Weverling GJ; Bayat B; Custers JH; Dubois MC; Cohen J; Goudsmit J; Heppner DG
    Infect Immun; 2007 May; 75(5):2283-90. PubMed ID: 17307942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models.
    Penny MA; Verity R; Bever CA; Sauboin C; Galactionova K; Flasche S; White MT; Wenger EA; Van de Velde N; Pemberton-Ross P; Griffin JT; Smith TA; Eckhoff PA; Muhib F; Jit M; Ghani AC
    Lancet; 2016 Jan; 387(10016):367-375. PubMed ID: 26549466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.
    Kester KE; McKinney DA; Tornieporth N; Ockenhouse CF; Heppner DG; Hall T; Krzych U; Delchambre M; Voss G; Dowler MG; Palensky J; Wittes J; Cohen J; Ballou WR;
    J Infect Dis; 2001 Feb; 183(4):640-7. PubMed ID: 11170991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.
    Gordon DM; McGovern TW; Krzych U; Cohen JC; Schneider I; LaChance R; Heppner DG; Yuan G; Hollingdale M; Slaoui M
    J Infect Dis; 1995 Jun; 171(6):1576-85. PubMed ID: 7769295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific.
    Alloueche A; Milligan P; Conway DJ; Pinder M; Bojang K; Doherty T; Tornieporth N; Cohen J; Greenwood BM
    Am J Trop Med Hyg; 2003 Jan; 68(1):97-101. PubMed ID: 12556156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of phase 3 trial of RTS, S/AS01 malaria vaccine: The need for an alternative development plan.
    Mahmoudi S; Keshavarz H
    Hum Vaccin Immunother; 2017 Sep; 13(9):2098-2101. PubMed ID: 28272979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children.
    Bojang KA; Olodude F; Pinder M; Ofori-Anyinam O; Vigneron L; Fitzpatrick S; Njie F; Kassanga A; Leach A; Milman J; Rabinovich R; McAdam KP; Kester KE; Heppner DG; Cohen JD; Tornieporth N; Milligan PJ
    Vaccine; 2005 Jul; 23(32):4148-57. PubMed ID: 15964483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants.
    Ajua A; Lell B; Agnandji ST; Asante KP; Owusu-Agyei S; Mwangoka G; Mpina M; Salim N; Tanner M; Abdulla S; Vekemans J; Jongert E; Lievens M; Cambron P; Ockenhouse CF; Kremsner PG; Mordmüller B
    Malar J; 2015 Feb; 14():72. PubMed ID: 25885325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection.
    Foquet L; Hermsen CC; van Gemert GJ; Van Braeckel E; Weening KE; Sauerwein R; Meuleman P; Leroux-Roels G
    J Clin Invest; 2014 Jan; 124(1):140-4. PubMed ID: 24292709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease.
    Penny MA; Pemberton-Ross P; Smith TA
    Malar J; 2015 Nov; 14():437. PubMed ID: 26537608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial.
    Aide P; Aponte JJ; Renom M; Nhampossa T; Sacarlal J; Mandomando I; Bassat Q; Manaca MN; Leach A; Lievens M; Vekemans J; Dubois MC; Loucq C; Ballou WR; Cohen J; Alonso PL
    PLoS One; 2010 Nov; 5(11):e13838. PubMed ID: 21079803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systems analysis of protective immune responses to RTS,S malaria vaccination in humans.
    Kazmin D; Nakaya HI; Lee EK; Johnson MJ; van der Most R; van den Berg RA; Ballou WR; Jongert E; Wille-Reece U; Ockenhouse C; Aderem A; Zak DE; Sadoff J; Hendriks J; Wrammert J; Ahmed R; Pulendran B
    Proc Natl Acad Sci U S A; 2017 Feb; 114(9):2425-2430. PubMed ID: 28193898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants.
    ; Agnandji ST; Lell B; Fernandes JF; Abossolo BP; Methogo BG; Kabwende AL; Adegnika AA; Mordmüller B; Issifou S; Kremsner PG; Sacarlal J; Aide P; Lanaspa M; Aponte JJ; Machevo S; Acacio S; Bulo H; Sigauque B; Macete E; Alonso P; Abdulla S; Salim N; Minja R; Mpina M; Ahmed S; Ali AM; Mtoro AT; Hamad AS; Mutani P; Tanner M; Tinto H; D'Alessandro U; Sorgho H; Valea I; Bihoun B; Guiraud I; Kaboré B; Sombié O; Guiguemdé RT; Ouédraogo JB; Hamel MJ; Kariuki S; Oneko M; Odero C; Otieno K; Awino N; McMorrow M; Muturi-Kioi V; Laserson KF; Slutsker L; Otieno W; Otieno L; Otsyula N; Gondi S; Otieno A; Owira V; Oguk E; Odongo G; Woods JB; Ogutu B; Njuguna P; Chilengi R; Akoo P; Kerubo C; Maingi C; Lang T; Olotu A; Bejon P; Marsh K; Mwambingu G; Owusu-Agyei S; Asante KP; Osei-Kwakye K; Boahen O; Dosoo D; Asante I; Adjei G; Kwara E; Chandramohan D; Greenwood B; Lusingu J; Gesase S; Malabeja A; Abdul O; Mahende C; Liheluka E; Malle L; Lemnge M; Theander TG; Drakeley C; Ansong D; Agbenyega T; Adjei S; Boateng HO; Rettig T; Bawa J; Sylverken J; Sambian D; Sarfo A; Agyekum A; Martinson F; Hoffman I; Mvalo T; Kamthunzi P; Nkomo R; Tembo T; Tegha G; Tsidya M; Kilembe J; Chawinga C; Ballou WR; Cohen J; Guerra Y; Jongert E; Lapierre D; Leach A; Lievens M; Ofori-Anyinam O; Olivier A; Vekemans J; Carter T; Kaslow D; Leboulleux D; Loucq C; Radford A; Savarese B; Schellenberg D; Sillman M; Vansadia P
    N Engl J Med; 2012 Dec; 367(24):2284-95. PubMed ID: 23136909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The RTS,S/AS01 malaria vaccine in children aged 5-17 months at first vaccination].
    Vandoolaeghe P; Schuerman L
    Pan Afr Med J; 2018; 30():142. PubMed ID: 30374388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adults.
    Leroux-Roels G; Leroux-Roels I; Clement F; Ofori-Anyinam O; Lievens M; Jongert E; Moris P; Ballou WR; Cohen J
    Hum Vaccin Immunother; 2014; 10(8):2211-9. PubMed ID: 25424924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.